TIMP1 and breast carcinoma: We have previously found that tumors derived from MDA-MB-231 human breast cancer cells orthotopically implanted in mice show evidence of gelatinase activity, and that treatment of MDA-MB-231 cells with tissue inhibitor of metalloproteinases-1 (TIMP-1) can reduce cellular invasiveness [29].